Tag: Cguard EPS
SIBERIA trial: Positive one-month results for embolic prevention system
InspireMD has announced positive interim results from the SIBERIA trial, an investigator-initiated study of the CGuard embolic prevention system (EPS). The data were presented...
Regulatory and reimbursement approval of CGuard EPS in Australia
CGuard Embolic Prevention System (EPS) (InspireMD) has been granted regulatory approval by the Therapeutic Goods Administration (part of the Australian Government’s Department of Health)...
Expanded two-year follow-up results from the PARADIGM clinical study using CGuard...
Piotr Musiałek, from the Department of Cardiac and Vascular Diseases, John Paul II Hospital, Kraków, Poland, presented the expanded 24-month follow-up results from the...
InspireMD announces expansion of its distribution network for CGuard EPS
InspireMD has announced it has signed Diverse Devices as its exclusive distributor for Australia and New Zealand, and has signed Do Gia Production...
